Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOCE (Bendamustine, Ofatumumab, Carboplatin, Etoposide) in Refractory/Relapsed Aggressive B-cell Lymphoma
NCT01458366Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2011
- Primary completion
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, ofatumumab in diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma (MCL), Follicular lymphoma (FL), Primary Mediastinal B-Cell Lymphoma (PMBCL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2011; status: completed.
02
Drugs
bendamustineofatumumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Mantle cell lymphoma (MCL)Follicular lymphoma (FL)Primary Mediastinal B-Cell Lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT01458366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458366.